Boehringer Ingelheim Outpaces the Market yet Again in 2007
30 April 2008
Boehringer Ingelheim enjoyed continued success through 2007, its growth outpacing the pharmaceuticals market for the eighth time in succession. As the Company announced at its annual press conference in Ingelheim, turnover rose by +8.8% in local currency (+3.6% in euro terms) to almost €11 billion (2006: €10.5 billion). At €2.1 billion, operating income - comparable to the EBIT - is at the previous year's level. This corresponds to an operative margin (ratio of operating income to net sales) of 19.2%. Income after tax was a good €1.8 billion, signifying an increase of +4.8% over the previous year. The number of employees worldwide rose by almost 1,400 to around 39,800 (an increase of +3.6%).
According to calculations by the healthcare information service, IMS, Boehringer Ingelheim grew by +7.1%, thus once again outpacing the pharmaceutical market which experienced growth of +6.0%. In 2007, Boehringer Ingelheim again secured a stable market share of almost 2%, ranking 15th among the international pharmaceutical companies.
BOEHRINGER INGELHEIM'S BUSINESS AREAS
Business in the most important strategic business area, Human Pharmaceuticals, Prescription Medicines accounts for 79% of the total net sales of Boehringer Ingelheim. Here, net sales rose in 2007 by almost +10% in local currency terms (+4.2% in euro terms) to over €8.6 billion, following adjustment to take account of the currency component. The self-medication business increased by +11.7% in local currency terms (+7.2% in euro terms) to €1.14 billion.
Total net sales of the Industrial Customer business(Biopharmaceuticals, Pharmaceuticals Production and Pharma Chemicals) amounted to EUR 739 million.
The growth of Boehringer Ingelheim in 2007 was evident in all three regions. Last year, North and South America was again the region with the strongest turnover of the company, where net sales exceeded EUR 5.4 billion (2007: EUR 5.3 billion). In spite of stagnating development in euro terms, the USA remains the principal driving force for growth and, with its net sales of €4.5 billion (approx. +12% in local currency terms), made the largest contribution to global net sales and profits.
The strongest growth amongst the regions was achieved in Europe with net sales of €3.6 billion (+ 8.6% in local currency terms) and a share of total net sales of just under 33%. The strongest country in this region was once again Germany with total net sales of €853 million, although prescription medicines accounted for only €444 million of this figures.
